Novare Pharmaceuticals Launched to Specialize in RHAMM Modulation
Emerging product development and commercialization company Allied Minds has just launched a divisional biopharmaceutical company that will specialize in the utilization of a protein called, RHAMM or Receptor for Hyaluronan Mediated Motility, for the creation of products indicated to enhance the body’s natural reparative mechanisms. The company, Novare Pharmaceuticals, is aiming to develop products patients with inflammatory disorders, such as Idiopathic Pulmonary Fibrosis (IPF), can benefit from.
RHAMM, which started off as a dermal filler for aesthetic purposes, was recently discovered by Dr. Eva Turley to have a potential application in some of today’s most difficult to treat diseases. Dr. Turley, a cancer researcher at the London Health Sciences Centre (LHSC) in London, Ontario, is working with MJ Bissell, one of the most prominent cell biologists in the world, to study the possible uses of RHAMM modulation in conditions like arthritis, keloid scarring, infantile Bronchopulmonary Dysplasia (BPD), and IPF.
IPF is a rare disease characterized by spontaneous scarring of lung tissue, which gradually and irreversibly reduces lung function and can severely reduce quality of life, before life-threatening respiratory failure. RHAMM is normally an intercellular substance, but Dr. Turley, who is also the current Chief Scientific Officer of Novare, is leading the study on modulating its secretion for the purpose of controlling natural cell movement and stem cell differentiation. According to Dr. Turley and her research team, this method is the safest and most effective approach to reducing inflammation and subsequent fibrosis.
In other news on pulmonary fibrosis, a study recently presented during this year’s European Respiratory Society International Congress (ERS) showed that treatment with nintedanib slowed the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF).